GREEN REVERSE-PHASE – HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY APPROACH FOR STABILITY-INDICATING SIMULTANEOUS QUANTIFICATION OF DORAVIRINE, LAMIVUDINE, AND TENOFOVIR IN BULK AND DOSAGE FORMS

Authors

  • SUBHRANSHU PANDA Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India.
  • SIRISHA GORANTLA Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India. https://orcid.org/0009-0000-4360-438X

DOI:

https://doi.org/10.22159/ajpcr.2025v18i10.55316

Keywords:

Doravirine, Lamivudine, Tenofovir,, International council for harmonization guidelines, Retention time

Abstract

Objective: A simple, accurate, and validated reverse-phase high-performance liquid chromatography (HPLC) method was developed for the simultaneous estimation of doravirine, lamivudine, and tenofovir in pharmaceutical formulations.

Methods: Chromatographic separation was achieved using a Zorbax Eclipse Plus C18 column (2.1×150 mm, 5 μm) with a mobile phase composed of 0.01 M potassium phosphate buffer (pH adjusted with orthophosphoric acid) and HPLC-grade acetonitrile, delivered at a flow rate of 1 mL/min. Detection was performed at 244 nm.

Results: The method yielded sharp, well-resolved peaks with retention times of 2.195 min for doravirine, 2.715 min for lamivudine, and 3.676 min for tenofovir. A peak resolution of 4.4 confirmed efficient separation. The method exhibited excellent linearity with a correlation coefficient (R²) of 0.9999 across concentration ranges of 2.515 μg/mL for doravirine and 7.545 μg/mL for both lamivudine and tenofovir. Accuracy was confirmed through recovery studies, yielding 100.02% for doravirine, 100.09% for lamivudine, and 99.98% for tenofovir. The method also demonstrated high sensitivity, with limits of detection of 0.01 μg/mL for doravirine and 0.11 μg/mL for both lamivudine and tenofovir. The respective limits of quantification were 0.04 μg/mL, 0.32 μg/mL, and 0.34 μg/mL. The regression equations derived were as follows: y=30936x +3374.3 for doravirine, y=29559x+889.66 for lamivudine, and y=29768x+3035.2 for tenofovir.

Conclusion: In addition to its strong analytical performance, the method was evaluated using the AGREE metric for green analytical chemistry compliance. Despite the use of acetonitrile, it achieved an AGREE score of 0.73, indicating good environmental compatibility due to minimal solvent consumption, energy efficiency, and avoidance of derivatization. This method – with its short runtime, high accuracy, cost-effectiveness, and environmentally responsible design – is highly suitable for routine quality control and stability studies of antiretroviral pharmaceutical formulations.

Downloads

Download data is not yet available.

References

1. Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb Perspect Med. 2012;2(10):a006882. doi: 10.1101/cshperspect.a006882, PMID 23028129

2. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9(5):227-41. doi: 10.4254/ wjh.v9.i5.227, PMID 28261380

3. Bamford A, Hamzah L, Turkova A. Paediatric antiretroviral therapy challenges with emerging integrase resistance. Curr Opin HIV AIDS. 2024;19(6):323-9. doi: 10.1097/COH.0000000000000876 PMID 38967797

4. Blanco-Arévalo JL, García-Deltoro M, Torralba M, Vélez-Díaz-Pallarés M, Castro A, Rubio-Rodríguez D, et al. HIV-1. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: A systematic literature review. AIDS Rev. 2024;26(2):67-79. doi: 10.24875/ AIDSRev.24000011, PMID 39134019

5. Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, et al. Switching to Doravirine/Lamivudine/Tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: Results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81(4):463-72. doi: 10.1097/QAI.0000000000002056, PMID 30985556

6. Bhaskararao P, Sarika M, Madhavi CL, Kollipara MG, Prashanthi G. The industrial importance of technology transfer for analytical method development and validation-application to vilazodone hydrochloride Dosage Form. Int J Chem Res. 2024;8(4):12-7. doi: 10.22159/ ijcr.2024v8i4.235

7. Kokkirala TK, Kancherla P, Alegete P, Suryakala D. A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form. Biomed Chromatogr. 2021;35(8):e5121. doi: 10.1002/bmc.5121 PMID 33760252

8. Tiruveedhi VL, Rao B, Babu K, Tejeswarudu B. Novel determination of anti-hypertensive combination; Benidipine hydrochloride andnebivolol hydrochloride by high performance chromatographic method. Res J Pharm Technol. 2021;14(10):5433-8. doi: 10.52711/0974- 360X.2021.00947

9. Pandit RK, Pandey V. Development and validation of a gradient program RP-HPLC method for estimation of multiple active pharmaceutical ingredients in an oral suspension taste masked with an ion exchange resin. Int J App Pharm. 2025;17(4):370-86. doi: 10.22159/ ijap.2025v17i4.53547

10. Gupta A, Kossambe RV, Moorkoth S. Box-Behnken design assisted eco-friendly RP-HPLC-PDA method for the quantification of paclitaxel: Application to evaluate the solubility of paclitaxel-cyclodextrin complex. Int J App Pharm. 2024;16(6):305-15. doi: 10.22159/ ijap.2024v16i6.51690

11. Damle MC, Khairnar R. Method for Simultaneous Estimation of lamivudine, tenofovir disoproxil fumarate, and Doravirine. Int J Pharm Pharm Sci. 2023;15(9):42-9. doi: 10.22159/ ijpps.2023v15i9.48681

12. Balaji NT, Abhilasha M, Manoj SC. Validated stability-indicating assay UHPLC method for simultaneous estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in pure material and pharmaceutical matrix. Bio Res App Chem. 2023;13(1):1-14. doi: 10.33263/BRIAC131.020

Published

07-10-2025

How to Cite

SUBHRANSHU PANDA, and SIRISHA GORANTLA. “GREEN REVERSE-PHASE – HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY APPROACH FOR STABILITY-INDICATING SIMULTANEOUS QUANTIFICATION OF DORAVIRINE, LAMIVUDINE, AND TENOFOVIR IN BULK AND DOSAGE FORMS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 18, no. 10, Oct. 2025, pp. 30-36, doi:10.22159/ajpcr.2025v18i10.55316.

Issue

Section

Original Article(s)